Trial Profile
A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- 09 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 28 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology